Novonesis (Novozymes) A/S Total Assets
Novonesis (Novozymes) A/S total assets. Based on the latest financial reports, Novonesis (Novozymes) A/S (NSIS-B) holds total assets worth Dkr16.52 Billion DKK (≈ $2.59 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how efficiently does Novonesis (Novozymes) A/S generate cash for how efficiently the company converts equity into cash flow.
Total Assets of Novonesis (Novozymes) A/S (2002–2025)
Total assets of Novonesis (Novozymes) A/S from 2002 to 2025. This chart illustrates how Novonesis (Novozymes) A/S's total assets have evolved over time, based on quarterly financial data. See NSIS-B live share price for real-time trading data and today's change.
Novonesis (Novozymes) A/S - Asset Composition Analysis
Novonesis (Novozymes) A/S Total Assets Breakdown (December 2025)
Novonesis (Novozymes) A/S total assets breakdown as of December 2025. Novonesis (Novozymes) A/S's total assets of Dkr16.52 Billion consist of 12.1% current assets and 87.9% non-current assets. Explore Novonesis (Novozymes) A/S current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 1.7% |
| Accounts Receivable | Dkr869.40 Million | 5.3% |
| Inventory | Dkr772.20 Million | 4.7% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr4.90 Billion | 29.9% |
| Goodwill | Dkr6.19 Billion | 37.9% |
Asset Composition Trend (2002–2025)
This chart illustrates how Novonesis (Novozymes) A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Novonesis (Novozymes) A/S's current assets represent 12.1% of total assets in 2025, a decrease from 45.2% in 2002.
- Cash Position: Cash and equivalents constituted 1.7% of total assets in 2025, down from 10.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 66.0% of total assets, an increase from 6.0% in 2002.
- Asset Diversification: The largest asset category is goodwill at 37.9% of total assets.
Novonesis (Novozymes) A/S Competitors by Total Assets
Key competitors of Novonesis (Novozymes) A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
International Flavors & Fragrances Inc
NYSE:IFF
|
USA | $25.15 Billion |
|
Akzo Nobel NV
AS:AKZA
|
Netherlands | €13.95 Billion |
|
Incitec Pivot Ltd
AU:IPL
|
Australia | AU$8.40 Billion |
|
Luxi Chemical Group Co Ltd
SHE:000830
|
China | CN¥35.95 Billion |
|
Tibet GaoZheng Explosive Co Ltd
SHE:002827
|
China | CN¥3.09 Billion |
|
Zibo Qixiang Tengda Chemical Co Ltd
SHE:002408
|
China | CN¥23.70 Billion |
|
Jilin OLED Material Tech Co Ltd
SHG:688378
|
China | CN¥2.76 Billion |
|
Chongqing Zaisheng Tech Corp
SHG:603601
|
China | CN¥3.19 Billion |
Novonesis (Novozymes) A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.67 | 1.66 | 1.44 |
| Quick Ratio | 1.03 | 1.04 | 0.89 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr823.27 Million | Dkr775.70 Million | Dkr2.15 Billion |
Novonesis (Novozymes) A/S - Advanced Valuation Insights
This section examines the relationship between Novonesis (Novozymes) A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.16 |
| Latest Market Cap to Assets Ratio | 1.85 |
| Asset Growth Rate (YoY) | 7.6% |
| Total Assets | Dkr16.35 Billion |
| Market Capitalization | $30.27 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Novonesis (Novozymes) A/S's assets above their book value (1.85x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Novonesis (Novozymes) A/S's assets grew by 7.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Novonesis (Novozymes) A/S (2002–2025)
The table below shows the annual total assets of Novonesis (Novozymes) A/S from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr16.35 Billion ≈ $2.56 Billion |
+7.59% |
| 2024-12-31 | Dkr15.20 Billion ≈ $2.38 Billion |
-46.48% |
| 2023-12-31 | Dkr28.39 Billion ≈ $4.44 Billion |
+1.46% |
| 2022-12-31 | Dkr27.98 Billion ≈ $4.38 Billion |
+12.99% |
| 2021-12-31 | Dkr24.77 Billion ≈ $3.87 Billion |
+20.76% |
| 2020-12-31 | Dkr20.51 Billion ≈ $3.21 Billion |
+0.36% |
| 2019-12-31 | Dkr20.44 Billion ≈ $3.20 Billion |
+3.76% |
| 2018-12-31 | Dkr19.70 Billion ≈ $3.08 Billion |
+7.21% |
| 2017-12-31 | Dkr18.37 Billion ≈ $2.87 Billion |
-1.53% |
| 2016-12-31 | Dkr18.66 Billion ≈ $2.92 Billion |
+4.88% |
| 2015-12-31 | Dkr17.79 Billion ≈ $2.78 Billion |
-3.45% |
| 2014-12-31 | Dkr18.43 Billion ≈ $2.88 Billion |
+11.63% |
| 2013-12-31 | Dkr16.51 Billion ≈ $2.58 Billion |
+9.22% |
| 2012-12-31 | Dkr15.11 Billion ≈ $2.36 Billion |
+9.18% |
| 2011-12-31 | Dkr13.84 Billion ≈ $2.17 Billion |
+9.92% |
| 2010-12-31 | Dkr12.59 Billion ≈ $1.97 Billion |
+15.64% |
| 2009-12-31 | Dkr10.89 Billion ≈ $1.70 Billion |
+9.72% |
| 2008-12-31 | Dkr9.93 Billion ≈ $1.55 Billion |
+11.88% |
| 2007-12-31 | Dkr8.87 Billion ≈ $1.39 Billion |
+11.37% |
| 2006-12-31 | Dkr7.96 Billion ≈ $1.25 Billion |
+8.98% |
| 2005-12-31 | Dkr7.31 Billion ≈ $1.14 Billion |
+2.45% |
| 2004-12-31 | Dkr7.13 Billion ≈ $1.12 Billion |
-6.54% |
| 2003-12-31 | Dkr7.63 Billion ≈ $1.19 Billion |
-8.59% |
| 2002-12-31 | Dkr8.35 Billion ≈ $1.31 Billion |
-- |
About Novonesis (Novozymes) A/S
Novozymes A/S produces and sells industrial enzymes, functional proteins, and microorganisms in Denmark, rest of Europe, North America, the Asia Pacific, the Middle East, Africa, and Latin America. It provides biosolutions for the food and beverage industry, such as dairy, baking, beverage, meat, plant-based, functional, and other foods, as well as precision protein and early lie nutrition. The c… Read more